Whalesbook
Zydus Lifesciences Drives Oncology Access with Nivolumab Biosimilar Launch
Zydus Lifesciences Limited has made a significant advancement in cancer care by launching Tishtha™, the world's first biosimilar of the cancer immunotherapy drug Nivolumab, in India on January 22, 2026. This development is poised to enhance patient access to critical immuno-oncology treatments by offering the therapy at approximately a quarter of the cost of the original reference drug. Tishtha™ will be available in two dosages: 100 mg for ₹28,950 and 40 mg for ₹13,950. This strategic pricing and dual-strength availability are designed to optimize dosing for oncologists, minimize drug wastage, and improve the economic viability of immunotherapy. Zydus estimates that this initiative could benefit over five lakh (500,000) patients in India by increasing affordability and widening access. The launch follows a Delhi High Court ruling that cleared the way for Zydus to market the biosimilar, prioritizing public interest and patient access ahead of the patent expiry of Bristol Myers Squibb's original drug in May 2026.
Strategic Diversification and US Market Expansion
Beyond the domestic oncology market, Zydus Lifesciences is actively pursuing strategic growth opportunities. The company is reportedly in discussions to acquire US biopharmaceutical firm Ardelyx Inc., a move valued at approximately $1.6 billion. To facilitate this potential acquisition, Zydus is considering raising up to ₹5,000 crore through a Qualified Institutional Placement (QIP), a plan for which its board has already secured approval. Ardelyx has two commercial products in the US: IBSRELA and XYPHOZAH, with IBSRELA projected to generate significant revenue in the coming years.
Complementing its expansion efforts, Zydus's US subsidiary, Sentynl Therapeutics Inc., recently achieved a significant milestone with the U.S. Food and Drug Administration's (FDA) approval of ZYCUBO® (copper histidinate). Announced in mid-January 2026, ZYCUBO® is the first and only approved treatment for Menkes disease, a rare and severe genetic disorder affecting pediatric patients. This approval underscores Zydus's growing capabilities in developing treatments for rare and complex conditions.
Market Context and Valuation
Zydus Lifesciences operates in a dynamic pharmaceutical landscape, with its stock performance reflecting investor sentiment towards its strategic initiatives and product pipeline. The company's market capitalization stands at approximately ₹88,000 crore, with a P/E ratio around 18.27 as of January 2026. The launch of Tishtha™ positions Zydus to capitalize on the growing demand for affordable biosimilars in India, a market where advanced cancer therapies have historically been cost-prohibitive for many. The company's broader strategy, encompassing oncology, rare diseases, and international market expansion through acquisitions, indicates a focused approach to long-term growth and diversification.
Peer Comparison
While Zydus Lifesciences makes substantial moves in the oncology and rare disease segments, other major Indian pharmaceutical players are also active in expanding their biologics and specialty portfolios. Companies like Sun Pharmaceutical Industries and Dr. Reddy's Laboratories are key players in the generics and biosimilars space, with ongoing investments in complex generics and differentiated products. However, Zydus's pioneering launch of the first Nivolumab biosimilar in India and its recent USFDA approval for ZYCUBO® highlight its competitive edge in specific, high-impact therapeutic areas. The potential acquisition of Ardelyx would further position Zydus among the leading Indian firms actively pursuing global specialty and innovative medicine markets, differentiating it from peers focused primarily on generic drug manufacturing.